U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07275359) titled 'Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations' on Nov. 28.
Brief Summary: The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.
Study Start Date: March 01, 2026
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease (COPD)
Intervention:
DRUG: Metformin
All enrolled participants will receive open-label Metformin for a treatment period of 6 months.
Recruitment Status: NOT_YET_RECR...